Results 21 to 30 of about 1,848 (184)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension [PDF]

Pulmonary Circulation, 2022
Despite the increase in therapeutic options, parenteral prostacyclins remain the cornerstone in the medical management of pulmonary arterial hypertension (PAH).
Elizabeth Colglazier, Leah Stevens, Claire Parker, Hythem M. Nawaytou, Elena K. Amin, Jasmine Becerra, Martina Steurer, Jeffrey R. Fineman   +7 more
doaj   +2 more sources

Selexipag in the management of pulmonary arterial hypertension: an update [PDF]

Drug, Healthcare and Patient Safety, 2019
J Gerry Coghlan,1 Christina Picken,2 Lucie H Clapp21Department of Cardiology, Royal Free Hospital, London NW3 2QG, UK; 2Institute of Cardiovascular Sciences, University College London, London WC1E 6JF, UKAbstract: Selexipag is a compound that was ...
Coghlan JG, Picken C, Clapp LH
doaj   +3 more sources

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension

BMC Pulmonary Medicine, 2017
Background In this report, we describe the first successful case of transition from subcutaneous administration of treprostinil to selexipag in a patient with severe pulmonary arterial hypertension (PAH), by evaluating hemodynamic changes and exercise ...
Asuka Furukawa, Yuichi Tamura, Hiroya Iwahori, Masato Goto, Narutaka Ohashi, Teruo Okabe, Akio Kawamura   +6 more
doaj   +2 more sources

Transitions From Parenteral Prostacyclin Analogues to Selexipag in Patients With Pulmonary Arterial Hypertension. [PDF]

Pulm Circ
ABSTRACT Pulmonary arterial hypertension (PAH) is a progressive illness that may require therapy with parenteral prostacyclin pathway agents (PPA) (epoprostenol and treprostinil). These parenteral PPA's are continuous ambulatory infusions that require a high level of skill and knowledge to maintain safety and effectiveness.
Kuebel DJ, Collins AR, Jose A, Guido MR, Elwing JM.   +4 more
europepmc   +2 more sources

A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist

Drug Design, Development and Therapy, 2014
Matthias Hoch,1 Borje Darpo,2,3 Tatiana Remenova,4 Randall Stoltz,5 Meijian Zhou,2 Priska Kaufmann,1 Shirin Bruderer,1 Jasper Dingemanse1 1Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; 2iCardiac Technologies ...
Hoch M, Darpo B, Remenova T, Stoltz R, Zhou M, Kaufmann P, Bruderer S, Dingemanse J   +7 more
doaj   +1 more source

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Respiratory Research, 2021
Background The oral IP receptor agonist selexipag is approved for the long-term treatment of pulmonary arterial hypertension (PAH). Treatment interruptions should be avoided due to the progressive nature of the disease. An intravenous (IV) formulation of
Hans Klose, Kelly M. Chin, Ralf Ewert, Henning Gall, Joseph Parambil, David Poch, Hans-Jürgen Seyfarth, Lene N. Axelsen, Shu-Fang Hsu Schmitz, Claudia Stein, Ioana R. Preston   +10 more
doaj   +1 more source

Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension

Frontiers in Pharmacology, 2023
Objective: Adding selexipag to the combined treatment of endothelin receptor antagonists (ERA) and phosphodiesterase 5 inhibitor (PDE5i) reduces the risk of clinical worsening events in patients with pulmonary arterial hypertension (PAH) but at a ...
Wenxing Dong, Wenxing Dong, Zhe Zhang, Mingming Chu, Peng Gu, Min Hu, Lulu Liu, Jingbin Huang, Rong Zhang   +8 more
doaj   +1 more source

Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles

Pharmaceutical Biology, 2022
Context As an inhibitor cytochrome P450 family 2 subfamily C polypeptide 8 (CYP2C8), quercetin is a naturally occurring flavonoid with its glycosides consumed at least 100 mg per day in food.
Shun-bin Luo, Er-min Gu, Yu-ao Chen, Shi-chen Zhou, Chen Fan, Ren-ai Xu   +5 more
doaj   +1 more source

Long-Term Supervised Cardiac Rehabilitation After Balloon Pulmonary Angioplasty Improved Residual Exercise Pulmonary Hypertension in Patients With Chronic Thromboembolic Pulmonary Hypertension: A Two-Case Report. [PDF]

Pulm Circ
ABSTRACT Abnormal pulmonary hemodynamics during exercise may persist even after balloon pulmonary angioplasty (BPA) for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). We report two female patients who underwent long‐term supervised outpatient cardiac rehabilitation (CR) after BPA with continuous pulmonary vasodilators.
Suzuki Y, Nakano Y, Okazaki K, Ito M, Yoshimori A, Tsunoda M, Yoshida M, Mitsui T, Adachi S, Kimura A.   +9 more
europepmc   +2 more sources

Association of Pericardial Tamponade With Initiation of Sotatercept in a Patient With Eisenmenger Syndrome. [PDF]

Pulm Circ
ABSTRACT Eisenmenger syndrome (ES) represents an advanced stage of pulmonary arterial hypertension (PAH) associated with congenital heart disease. It is characterized by elevated pulmonary vascular resistance, with a right‐to‐left shunt and resting hypoxemia. ES is associated with high morbidity and mortality.
Aldawsari KA, Simpkin CT, Frank BS, Ivy DD.   +3 more
europepmc   +2 more sources